OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS Share Price
Certificat
DE000SW2EQR9
| Market Closed - Deutsche Boerse AG 20:47:40 24/05/2024 BST | ||
| 22.97 EUR | -2.46% |
|
| Current month | -20.96% | ||
| 1 month | -18.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24/05/24 | 22.97 | -2.46% |
| 23/05/24 | 23.55 | -1.55% |
| 22/05/24 | 23.92 | -1.60% |
| 21/05/24 | 24.31 | +2.44% |
| 20/05/24 | 23.73 | -0.75% |
Delayed Quote Deutsche Boerse AG
Last update May 24, 2024 at 08:47 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SW2EQR |
| ISIN | DE000SW2EQR9 |
| Date issued | 17/08/2023 |
| Strike | 705.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 32.07 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 34.18 € |
|---|---|
| Lowest since issue | 22.93 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
457
USD
Average target price
462.8
USD
Spread / Average Target
+1.28%
- Stock Market
- Certificates
- Certificat
